Pfizer/Eyetech Macugen ASP
Executive Summary
Pfizer/Eyetech's Macugen reimbursed at $1,054.70 per injection under Medicare Part B average sales price plus 6% model. Macugen, which FDA approved Dec. 17 for the treatment of neovascular (wet) age-related macular degeneration, carries a list price of $995 per injection (1"The Pink Sheet" Jan. 3, 2005, p. 7). Labeling recommends Macugen be administered every six weeks, bringing the treatment's annual cost based on list price to $7,960 per eye, and CMS' annual reimbursement per eye to $8,437.60 (2"The Pink Sheet" Jan. 10, 2005, p. 20)...
You may also be interested in...
Macugen Access Program Will Help Seniors With Medicare Copay
The Macugen Access Program will help seniors cover the 20% Medicare copay, Eyetech COO Paul Chaney said
Pfizer/Eyetech Macugen Clears FDA; Firms See Broad Medicare Coverage
Pfizer/Eyetech's launch of the ophthalmic agent Macugen should be helped by a relatively generous initial reimbursement under Medicare Part B
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”